Eli Lilly says a new once-a-week injection for those with Type Two diabetes is closer to hitting the market. The drug maker announced Wednesday Dulaglutide met its goals in a pair of late-phase studies. The new drug has been in development for over six years, and will likely be submitted to regulatory authorities later this year.